Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Prognosis and clinical presentation of BRCA2-associated breast cancer

Author:
  • Niklas Loman
  • O Johannsson
  • Pär-Ola Bendahl
  • N Dahl
  • Z Einbeigi
  • A Gerdes
  • Åke Borg
  • Håkan Olsson
Publishing year: 2000
Language: English
Pages: 1365-1373
Publication/Series: European Journal of Cancer
Volume: 36
Issue: 11
Document type: Journal article
Publisher: Elsevier

Abstract english

54 female breast cancer patients from 22 families with BRCA2 germ line mutations from Sweden and Denmark were compared with 214 age- and date of diagnosis-matched controls identified among breast cancer patients from South Sweden. At diagnosis, BRCA2-associated cases were more often node-positive (N+). OR=1.9 (95% confidence interval (CI)=1.0-3.6; P=0.036), and were more often clinical stage IV: OR=4.6 (95% CI=1.3-17; P=0.021) than the controls. Bilateral disease was also more common among the BRCA2-associated cases: OR=2. 4 (95% CI=1.1-5.3; P=0.027). Breast cancer-specific survival (BCSS) was significantly worse among the BRCA2-associated cases: RR=2.0 (95% CI=1.2-3.4; P=0.010). When stage was corrected for in a multivariate analysis, BCSS was no longer significantly worse for the BRCA2-associated cases: RR=1.6 (95% CI=0.85-3.1). The corresponding effect after correction for bilateral disease was: RR=1.8 (95% CI=1.0-3.1; P=0.034). The unfavourable prognosis in BRCA2-associated breast cancer seems, to a great extent, to be a consequence of the higher clinical stage at diagnosis. The increased presence of bilateral cancers appears to have less impact on survival in this group of hereditary breast cancer. Data presented here needs to be taken into account when counselling healthy carriers of BRCA2 germ line mutations.

Keywords

  • Cancer and Oncology
  • Prognosis
  • Stage
  • Hereditary
  • BRCA2
  • Breast cancer

Other

Published
  • ISSN: 1879-0852
Åke Borg
Åke Borg
E-mail: ake.borg [at] med.lu.se

Principal investigator

Oncology and Pathology, MV

+46 46 275 25 52

MV 404 C21B2

90

Project manager

Familial Breast Cancer

90

Professor

Oncology and Pathology, MV

MV 404 C21C2

90